Cancer Prevention

Questions discussed in this category

Would you restart endocrine therapy for a patient with new contralateral LCIS diagnosed 2 years following completion of AI therapy for stage 1A HR+ IDC?

Would you restart hormonal therapy in a patient with a new diagnosis of LCIS 2 years after they have completed 5 yrs of AI for stage 1A IDC in the oth...

1 Answer available

How would you approach breast cancer screening in an adolescent patient with a CDH1 mutation?

0 Answers available

When, if ever, would you recommend risk reducing BSO in patients with moderate penetrance breast cancer germline mutations?

Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylacti...

2 Answers available

For which non-BRCA pathogenic germline variants, if any, might you consider recommending chemoprevention with SERM/AI?

In a scenario where patient's other clinical/familial risk does not sufficiently qualify them? See JCO OGR 8/2021 by @Mark E. Robson discussing manag...

3 Answers available

How do you counsel patients on the efficacy of breast cancer risk reduction strategies such as breast MRI surveillance or bilateral mastectomy for those considered high risk by polygenic risk score, pathogenic variants, and/or family history?

Specifically do we know by how much each intervention reduces the risk of developing MBC or increase breast cancer specific as well as overall surviva...

3 Answers available

Would you recommend adjuvant tamoxifen in premenopausal woman with high grade DCIS and familial CHEK2 mutation who had bilateral mastectomies?

1 Answer available

How do you approach use of tamoxifen for chemo-prevention in post-menopausal women with non-BRCA germline mutations?

For instance, patients with ATM mutations

1 Answer available

When do you recommend endocrine therapy for chemoprevention in women with high risk benign breast lesions?

1 Answer available

For what patient groups (if any) do you routinely recommend screening colonoscopy prior to radiation for prostate cancer?

3 Answers available

How do you decide which lab to use for multi-gene hereditary testing?

Is there a difference among all the commercial genetic testing labs? Is there anything beyond CLIA- and CAP-certification that we should look for...